33 research outputs found
Disruption of the vacuolar-type H+-ATPase complex in liver causes MTORC1-independent accumulation of autophagic vacuoles and lysosomes
The vacuolar-type H+-translocating ATPase (v-H+-ATPase) has been implicated in the amino aciddependent activation of the mechanistic target of rapamycin complex 1 (MTORC1), an important regulator of macroautophagy. To reveal the mechanistic links between the v-H+-ATPase and MTORC1, we destablilized v-H+-ATPase complexes in mouse liver cells by induced deletion of the essential chaperone ATP6AP2. ATP6AP2-mutants are characterized by massive accumulation of endocytic and autophagic vacuoles in hepatocytes. This cellular phenotype was not caused by a block in endocytic maturation or an impaired acidification. However, the degradation of LC3-II in the knockout hepatocytes appeared to be reduced. When v-H+-ATPase levels were decreased, we observed lysosome association of MTOR and normal signaling of MTORC1 despite an increase in autophagic marker proteins. To better understand why MTORC1 can be active when v-H+-ATPase is depleted, the activation of MTORC1 was analyzed in ATP6AP2-deficient fibroblasts. In these cells, very little amino acid-elicited activation of MTORC1 was observed. In contrast, insulin did induce MTORC1 activation, which still required intracellular amino acid stores. These results suggest that in vivo the regulation of macroautophagy depends not only on v-H+-ATPase-mediated regulation of MTORC1.Peer reviewe
Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine
Influenza A viruses (IAVs) impact the public health and global economy by causing yearly epidemics and occasional pandemics. Several anti-IAV drugs are available and many are in development. However, the question remains which of these antiviral agents may allow activation of immune responses and protect patients against co- and re-infections. To answer to this question, we analysed immuno-modulating properties of the antivirals saliphenylhalamide (SaliPhe), SNS-032, obatoclax, and gemcitabine, and found that only gemcitabine did not impair immune responses in infected cells. It also allowed activation of innate immune responses in lipopolysaccharide (LPS)- and interferon alpha (IFN alpha)-stimulated macrophages. Moreover, immuno-mediators produced by gemcitabine-treated IAV-infected macrophages were able to prime immune responses in non-infected cells. Thus, we identified an antiviral agent which might be beneficial for treatment of patients with severe viral infections. (C) 2015 The Authors. Published by Elsevier B.V.Peer reviewe
Inhibition of Iron Uptake Is Responsible for Differential Sensitivity to V-ATPase Inhibitors in Several Cancer Cell Lines
Many cell lines derived from tumors as well as transformed cell lines are far more sensitive to V-ATPase inhibitors than normal counterparts. The molecular mechanisms underlying these differences in sensitivity are not known. Using global gene expression data, we show that the most sensitive responses to HeLa cells to low doses of V-ATPase inhibitors involve genes responsive to decreasing intracellular iron or decreasing cholesterol and that sensitivity to iron uptake is an important determinant of V-ATPase sensitivity in several cancer cell lines. One of the most sensitive cell lines, melanoma derived SK-Mel-5, over-expresses the iron efflux transporter ferroportin and has decreased expression of proteins involved in iron uptake, suggesting that it actively suppresses cytoplasmic iron. SK-Mel-5 cells have increased production of reactive oxygen species and may be seeking to limit additional production of ROS by iron
Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins
Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases.Peer reviewe
Antiviral properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins
Viral diseases remain serious threats to public health because of the
shortage of effective means of control. To combat the surge of viral
diseases, new treatments are urgently needed. Here we show that
small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins
(Bcl-2i), induced the premature death of cells infected with different
RNA or DNA viruses, whereas, at the same concentrations, no toxicity was
observed in mock-infected cells. Moreover, these compounds limited
viral replication and spread. Surprisingly, Bcl-2i also induced the
premature apoptosis of cells transfected with viral RNA or plasmid DNA
but not of mock-transfected cells. These results suggest that Bcl-2i
sensitizes cells containing foreign RNA or DNA to apoptosis. A
comparison of the toxicity, antiviral activity, and side effects of six
Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate.
Thus, our results pave the way for the further development of Bcl-2i for
the prevention and treatment of viral diseases.</p
Synthesis of Psymberin Analogues: Probing a Functional Correlation with the Pederin/Mycalamide Family of Natural Products
Studies toward the Unique Pederin Family Member Psymberin: Full Structure Elucidation, Two Alternative Total Syntheses, and Analogs
Two synthetic approaches to psymberin have been accomplished.
A
highly convergent first generation synthesis led to the complete stereochemical
assignment and demonstrated that psymberin and irciniastatin A are
identical compounds. This synthesis featured a diastereoselective
aldol coupling between the aryl fragment and a central tetrahydropyran
core and a novel one-pot procedure to convert an amide, via intermediacy
of a sensitive methyl imidate, to the <i>N</i>-acyl aminal
reminiscent of psymberin. The highlights of the second generation
synthesis include an efficient iridium-catalyzed enantioselective
bisallylation of neopentyl glycol and a stepwise Sonogashira coupling/cycloisomerization/reduction
sequence to construct the dihydroisocoumarin unit. The two synthetic
avenues were achieved in 17–18 steps (longest linear sequence,
∼14–15 isolations) from 3 fragments prepared in 7–8
(first generation) and 3–8 (second generation) steps each.
This convergent approach allowed for the preparation of sufficient
amounts of psymberin (∼ 0.5 g) for follow-up biological studies.
Meanwhile, our highly flexible strategy enabled the design and synthesis
of multiple analogs, including a psymberin–pederin hybrid,
termed psympederin, that proved crucial to a comprehensive understanding
of the chemical biology of psymberin and related compounds that will
be described in a subsequent manuscript
Rifamycin Biosynthetic Congeners: Isolation and Total Synthesis of Rifsaliniketal and Total Synthesis of Salinisporamycin and Saliniketals A and B
We describe the isolation,
structure elucidation, and total synthesis
of the novel marine natural product rifsaliniketal and the total synthesis
of the structurally related variants salinisporamycin and saliniketals
A and B. Rifsaliniketal was previously proposed, but not observed,
as a diverted metabolite from a biosynthetic precursor to rifamycin
S. Decarboxylation of rifamycin provides salinisporamycin, which upon
truncation with loss of the naphthoquinone ring leads to saliniketals.
Our synthetic strategy hinged upon a PtÂ(II)-catalyzed cycloisomerization
of an alkynediol to set the dioxabicyclo[3.2.1]Âoctane ring system
and a fragmentation of an intermediate dihydropyranone to forge a
stereochemically defined (<i>E</i>,<i>Z</i>)-dienamide
unit. Multiple routes were explored to assemble fragments with high
stereocontrol, an exercise that provided additional insights into
acyclic stereocontrol during stereochemically complex fragment-assembly
processes. The resulting 11–14 step synthesis of saliniketals
then enabled us to explore strategies for the synthesis and coupling
of highly substituted naphthoquinones or the corresponding naphthalene
fragments. Whereas direct coupling with naphthoquinone fragments proved
unsuccessful, both amidation and C–N bond formation tactics
with the more electron-rich naphthalene congeners provided an efficient
means to complete the first total synthesis of rifsaliniketal and
salinisporamycin
The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections
BACKGROUND AND PURPOSE: Cellular vacuolar ATPases (v-ATPase) play an important role in endosomal acidification, a critical step in influenza A virus (IAV) host cell infection. We investigated the antiviral activity of the v-ATPase inhibitor saliphenylhalamide (SaliPhe) and compared it with several older v-ATPase inhibitors concanamycin A, bafilomycin A1, (BafA) and archazolid B targeting the subunit c of the V(0) sector.
EXPERIMENTAL APPROACH: An in vitro assay was devised to quantify the anti-influenza effect of v-ATPase inhibitors by measuring green fluorescent protein fluorescence of a reporter IAV. These data were combined with cytotoxicity testing to calculate selectivity indices. Data were validated by testing v-ATPase inhibitors against wild-type IAV in vitro and in vivo in mice.
KEY RESULTS: In vitro SaliPhe blocked the proliferation of pandemic and multidrug resistant viruses at concentrations up to 51-fold below its cytotoxic concentrations. At essentially non-toxic concentrations, SaliPhe protected 62.5% of mice against a lethal challenge of a mouse-adapted influenza strain, while BafA at cytotoxic concentrations showed essentially no protection against infection with IAV (SaliPhe vs. BafA P < 0.001).
CONCLUSIONS AND IMPLICATIONS: Our results show that a distinct binding site of the proton translocation domain of cellular v-ATPase can be selectively targeted by a new generation v-ATPase inhibitor with reduced toxicity to treat influenza virus infections, including multi-resistant strains. Treatment strategies against influenza that target host cellular proteins are expected to be more resistant to virus mutations than drugs blocking viral proteins